Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
1
25%
Ph phase_2
2
50%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

unknown125%
recruiting250%
withdrawn125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_3

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT07165951
recruitingphase_2

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

NCT06767813
withdrawnphase_2

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

NCT05998941
unknownphase_1

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

NCT05198505

Clinical Trials (4)

Showing 4 of 4 trials
NCT07165951Phase 3

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Recruiting
NCT06767813Phase 2

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Recruiting
NCT05998941Phase 2

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Withdrawn
NCT05198505Phase 1

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4